The July 2026 PCAC Vote, Decoded: What “Recommended” Actually Means for Six Peptides

On July 23 and 24, 2026, a federal advisory committee spent two days at the FDA's White Oak campus deciding whether seven peptides should become eligible for compounding by licensed pharmacies. It voted yes on six of them.

Within hours, a substantial part of the peptide industry began describing this as approval. It was not approval. It was not legalization. As of today, not one of those six peptides can lawfully be compounded, and none of them is an FDA-approved drug.

What actually happened is more interesting than the headline, and considerably more consequential for anyone who follows this space. Here is the whole thing, in order.

What the PCAC is, and what it can't do

The Pharmacy Compounding Advisory Committee is a standing panel of outside experts that advises the FDA on questions about drug compounding. Its members are drawn from academia, industry, state government, clinical practice, the National Association of Boards of Pharmacy and the United States Pharmacopeia.

The committee reviews scientific evidence and votes on recommendations. That is the entire scope of its power. It does not write regulations, it does not approve drugs, and its votes carry no legal force. When the PCAC votes on a substance, the FDA receives that vote as advice it is free to accept, reject, or leave sitting indefinitely.

One caveat matters here: FDA staff noted during the July meeting that the agency rarely departs from PCAC recommendations. So a favorable vote is a meaningful signal about the likely destination. It is just not the destination itself.

The 503A Bulks List, and why a peptide needs to be on it

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding — a licensed pharmacy preparing a medication for an individual patient against a valid prescription. A pharmacy compounding under 503A can only use a bulk drug substance that satisfies one of three conditions:

1. The substance has an applicable USP or National Formulary monograph;
2. The substance is a component of an FDA-approved drug product; or
3. The substance appears on the FDA's 503A Bulk Drug Substances List.

None of the seven peptides reviewed in July satisfies any of the three. That is precisely why the meeting happened, and precisely why the meeting did not by itself change anything. The third door is the one being opened, and it opens by regulation, not by vote.

Why bulks-list inclusion is not an efficacy finding

This point is routinely mangled, so it is worth stating plainly. FDA drug approval requires a sponsor to demonstrate safety and effectiveness through clinical trials. Bulks-list evaluation asks a narrower set of questions: can the substance be adequately characterized for identity, purity and potency; does it present significant safety risks in compounded preparations; and is there enough published literature to inform safe compounding?

A substance can clear that bar without anyone having established that it works. Inclusion on the bulks list means a substance can be handled responsibly in a compounding pharmacy. It does not mean it treats anything.

How the seven peptides got to a vote at all

In September 2023, the FDA placed more than a dozen peptides into Category 2 of the 503A bulks framework. Category 2 was the designation for substances the agency had evaluated and found to carry significant safety risks — in this case citing immunogenicity, impurity concerns, and thin human clinical data. The practical effect was a prohibition: pharmacies could not compound them.

That held until early 2026, when the political weather changed. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that many Category 2 peptides would be considered for reclassification. On April 15, 2026, he confirmed the removal of twelve peptides from Category 2, following withdrawal of the nominations by the original nominators.

The twelve: BPC-157, TB-500, MOTS-c, injectable GHK-Cu, Melanotan II, Semax, PEG-MGF, emideltide (DSIP), Epitalon, KPV, cathelicidin LL-37, and dihexa acetate.

The two days, and how the votes actually fell

Each peptide got the same treatment: an open public comment session, a presentation and recommendation from FDA scientists, and a question-and-answer exchange with committee members. The agency considered the free base and acetate forms of each peptide separately, which turned seven peptide families into fourteen discrete questions.

Note the indications in that third column. These are the specific uses the FDA selected for regulatory review, not a menu of endorsed applications. BPC-157 was evaluated for ulcerative colitis, not for tendon repair — which is what most people who search for it are actually thinking about.

The detail almost nobody reported

FDA's own scientists recommended against inclusion. For all seven. Their stated reasons were consistent: insufficient safety data, insufficient efficacy data, and inadequate characterization of the molecules themselves.

The committee overrode that recommendation six times out of seven.

That is an unusual posture for an advisory committee, and it is the single most important fact for predicting what happens next. The agency now has to decide how to handle a set of recommendations that its own review staff opposed.

What the two sides argued

Opponents in the public session pressed three points: that formulation variation across the industry makes these substances hard to characterize consistently; that clinical safety and efficacy data and adverse-event reporting are both thin; and that inclusion would be widely misread as FDA endorsement. Their proposed alternative was straightforward — sponsors who believe these compounds work should pursue formal drug approval.

Supporters countered that licensed practitioners have used these peptides for years, that real unmet patient need exists, and that the molecules are simple enough that intellectual property protection is difficult — removing the commercial incentive that normally funds a formal approval program. Their strongest argument was structural: bringing these compounds inside the regulated compounding system would subject them to more oversight than the current gray market provides, not less.

Where things actually stand today

The FDA is reviewing the recommendations. To formally add any peptide to the 503A Bulks List, it must run notice-and-comment rulemaking — publish a proposed rule, take public comment, and issue a final rule. Observers expect proposed rules could appear in late 2026 or 2027, and the full process could stretch over multiple years.

There is a shorter path that has been widely discussed but has not happened: the agency could grant interim Category 1 status or otherwise signal enforcement discretion for the recommended six while rulemaking proceeds. Category 1 substances are subject to enforcement discretion and may be used in compounding even though they are not technically on the official list. If that happens, access changes quickly. It has not happened yet.

Two things worth watching

State boards are not waiting for Washington. State pharmacy boards regulate compounding inside their own jurisdictions and can be stricter than federal baseline. Ohio's Board of Pharmacy, for example, has issued explicit guidance that Category 2 and Category 3 peptides cannot be compounded, and has taken enforcement action — including summary suspension in some cases — against pharmacies compounding substances such as BPC-157 and CJC-1295/ipamorelin. How state boards respond to the PCAC vote is genuinely unsettled.

There is a second meeting coming. The PCAC will convene again before the end of February 2027 to consider five more peptides: cathelicidin LL-37, GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF. Several PCAC members also conditioned their July votes on safeguards — authorized API sourcing, adverse-event reporting requirements, formulation limits — which may shape whatever rule eventually emerges.

The short version